Holen Sie sich die Stockscreener-App
32.18
0.53%
-0.17
Handel nachbörslich:
32.18
Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten
IDEAYA Biosciences (NASDAQ:IDYA) Stock Price Down 3.5%Should You Sell? - MarketBeat
Ideaya Biosciences Stock Not Fully Reflecting Phase 2/3 Data From Metastatic Uveal Melanoma Study, RBC Says - marketscreener.com
Trio of Bay Area cancer-fighting companies look to raise $1 billion on solid clinical trials - The Business Journals
Guggenheim raises Ideaya Biosciences stock price target on trial data By Investing.com - Investing.com Canada
RBC Capital raises Ideaya Biosciences stock price target on trial data - Investing.com Canada
Novo teams with OpenAI; Ideaya gets muted response to eye drug data - Yahoo Finance
IDEAYA Biosciences Unveils OptimUM-02 Data: Darovasertib/Crizotinib Doubles PFS in Uveal Melanoma - Yahoo Finance
IDEAYA Biosciences, Inc. (IDYA) Discusses Topline Results from OptimUM-02 Trial Evaluating Darovasertib and Crizotinib in HLA-A2-Negative Metastatic Uveal MelanomaSlideshow (NASDAQ:IDYA) 2026-04-13 - Seeking Alpha
IDEAYA Biosciences, Inc. (IDYA) Latest Stock News & Headlines - Yahoo Finance
Mizuho raises Ideaya Biosciences stock price target on trial data By Investing.com - Investing.com Canada
Ideaya Biosciences: Stock Buoyant On Good mUM DataBut Approval Not A Formality (IDYA) - Seeking Alpha
Truist raises Ideaya Biosciences stock price target on trial data By Investing.com - Investing.com Canada
IDEAYA’s uveal melanoma drug combo meets trial goals By Investing.com - Investing.com Australia
Goldman Sachs raises Ideaya Biosciences stock price target on trial data By Investing.com - Investing.com South Africa
Goldman Sachs raises Ideaya Biosciences stock price target on trial data - Investing.com Canada
IDEAYA Biosciences (IDYA) Stock Jumps 26% After Eye Cancer Trial Blows Past Standard Care - MEXC
IDEAYA Biosciences Announces Phase 2/3 Clinical Update for Darovasertib Combination in OptimUM-02 Trial - Minichart
IDEAYA and Servier's eye cancer drug meets trial goal, paving way for FDA application - Reuters
IDEAYA Biosciences (IDYA) Soars 26% on Breakthrough Eye Cancer Trial Data - MEXC
Shares of This Cancer Therapy Maker Are Up 14%. Here’s Why. - Barron's
IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock SoarsIDEAYA Biosciences (NASDAQ:IDYA) - Benzinga
IDYA: Darovasertib plus crizotinib doubled PFS and improved ORR in HLA-A*02:01-negative mUM - TradingView — Track All Markets
IDEAYA Biosciences stock surges 27% on trial results - Investing.com
IDEAYA’s uveal melanoma drug combo meets trial goals - Investing.com
IDEAYA Biosciences' darovasertib+crizotinib cuts progression risk 58%, median PFS 6.9 vs 3.1 months - TradingView — Track All Markets
Darovasertib combo boosts PFS in IDEAYA (NASDAQ: IDYA) uveal melanoma trial - Stock Titan
IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma - PR Newswire
Why IDEAYA Biosciences Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Dip Buying: Can IDEAYA Biosciences Inc reach all time highs this year2026 Momentum & Low Risk Growth Stock Ideas - baoquankhu1.vn
Why Is Ideaya Biosciences (IDYA) Stock Surging Over 20% Overnight? - Stocktwits
IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026 - BioSpace
IDEAYA Biosciences to Announce Topline Results from Phase 2/3 Op - GuruFocus
IDYA Stock Pops As New Cancer Trials Ignite Trader Focus - timothysykes.com
Ideaya Biosciences to announce topline results from phase 2/3 Optimum-02 trial in metastatic uveal melanoma on Monday, April 13, 2026 - marketscreener.com
Ideaya Biosciences To Announce Topline Results From Phase 2/3 Optimum-02 Trial In Metastatic Uveal Melanoma On Monday, April 13, 2026 - TradingView — Track All Markets
IDEAYA to report uveal melanoma trial results Monday By Investing.com - Investing.com UK
IDEAYA to reveal April 13 trial data in metastatic uveal melanoma - Stock Titan
(IDYA) Volatility Zones as Tactical Triggers - Stock Traders Daily
IDEAYA’s April 13 PFS Results May Lead to Fast-Track Approval or Significant Revaluation - Bitget
Ideaya Biosciences announces clinical collaboration with AstraZeneca for lung cancer study - Investing.com
IDEAYA, AstraZeneca launch global IDE849-Imfinzi lung cancer trial - TipRanks
Ideaya Biosciences Incenters clinical collaboration agreement with AstraZeneca on April 8, 2026SEC filing - marketscreener.com
IDEAYA Biosciences IncAdvancing Global Pha - Moomoo
IDEAYA Biosciences (NASDAQ: IDYA) teams with AstraZeneca on IDE849-Imfinzi SCLC trial - Stock Titan
Ideaya Biosciences: Key Pivotal Data Imminent - Seeking Alpha
IDEAYA Biosciences Advances IDE574 Into Phase 1 As First Patient Enrolled For KAT6 And KAT7 Dual Inhibitor - BioPharma APAC
IDEAYA Biosciences, Inc. (IDYA) stock price, news, quote and history - Yahoo Finance UK
Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH), IDEAYA Biosciences (IDYA) and Bristol-Myers Squibb (BMY) - The Globe and Mail
Jefferies Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $52 - Moomoo
IDEAYA Biosciences Target of Unusually Large Options Trading (NASDAQ:IDYA) - MarketBeat
Ideaya enrolls first patient in phase 1 trial of KAT6/7 inhibitor - Investing.com Canada
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer - TradingView — Track All Markets
IDEAYA Biosciences announced that the first patient has been dosed in a Phase I clinical trial of Ide574, its potential first-in-class dual inhibitor targeting Kat6/7. - Bitget
IDYA PE Ratio & Valuation, Is IDYA Overvalued - Intellectia AI
Why IDEAYA Biosciences (IDYA) Is Up 7.5% After Early Data From First-in-Class Cancer Combo - Yahoo Finance
A Look At IDEAYA Biosciences (IDYA) Valuation After New DLL3 Combo Trial Progress And Early Responses - Yahoo Finance
IDEAYA Biosciences, Inc. $IDYA Position Decreased by JPMorgan Chase & Co. - MarketBeat
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):